Acute Porphyria Drug Database

B01AC24 - Ticagrelor
Propably not porphyrinogenic
PNP

Side effects
Common adverse reactions of ticagrelor that can be confused with symptoms of an acute porphyric attack are nausea and constipation.
Rationale
Ticagrelor is metabolized by CYP 3A4, and has potential for modulating the activity of both CYP 3A4 and CYP 2C9 by mechanisms including activation and inhibition. The inhibition of CYP 3A4 is possibly the most pronounced effect, but this is not a mechanism-based inhibition. The activating effect of CYP 3A4 is not due to induction according to in vitro findings. Ticagrelor has shown in vitro to be a CYP 2C9 inhibitor and activator, but these effects are very weak, and not shown in vivo. Ticagrelors interactions with CYP enzymes are not considered to have porphyrinogenic potential.
Chemical description
Ticagrelor is a cyclopentyltriazolopyrimidine.
Therapeutic characteristics
Ticagrelor is a platelet aggregation inhibitor that is co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients. It is administered orally.
Metabolism and pharmacokinetics
Ticagrelor is mainly metabolized by CYP 3A4. The major metabolite of ticagrelor is AR-C124910XX, which is also active as assessed by in vitro binding to the platelet P2Y12 ADP-receptor. The systemic exposure to the active metabolite is approximately 30-40% of that obtained for ticagrelor. Ticagrelor has a half-life of 7 hours, while its active metabolite has a half-life of 9 hours. Ticagrelor is a mild inhibitor and activator of CYP 3A4 (SPC, EMA assessment report). In a drug-drug interaction study the AUC of the CYP 3A4 substrate simvastatin was increased by 56% and the Cmax by 81%, indicating that ticagrelor is a mild inhibitor of CYP 3A4 (Teng 2013a). In vitro studies using preincubation methods showed that the inhibition of CYP 3A4 is not mechanism-based. (Zhou 2011). In an in-vivo study ticagrelor was found to be a week activator (and inhibitor) of the metabolism of midazolam (Teng 2013b). However, the activation of CYP 3A4 is shown in vitro not to be caused by induction (Zhou 2011). Zhou et al (2011) also found ticagrelor to be a weak inducer of CYP 2B6 and 2C9, but the induction was only observed at concentrations 13 times above therapeutic Cmax. In the same study modest inhibition of CYP 2C9 was also reported. In a study with healthy volunteers ticagrelor did not alter the metabolism of the CYP 2C9 substrate tolbutamide, and it is not expected that ticagrelor has interaction potential with drugs metabolized by CYP 2C9 (Teng 2013c).

References

  1. Scientific articles
  2. Teng R, Butler K. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers. Clin Ther. 2013b Jul;35(7):1025-37. #3184
  3. Teng R, Mitchell P et al. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. Int J Clin Pharmacol Ther. 2013c Apr;51(4):305-12. #3185
  4. Teng R, Mitchell PD et al. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013a Mar;69(3):477-87 #3183
  5. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012 May 1;51(5):305-18 PMID 22489610. #3182
  6. Drug reference publications
  7. DrugBank. Ticagrelor. #3181
  8. Government bodies
  9. European Medicines Agency (EMA). Assessment report for Brilique. 2011 [online #3180
  10. Summary of Product Characteristics
  11. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Brilique. #3186

Similar drugs
Explore alternative drugs in similar therapeutic classes B01A / B01AC or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙